ML20217B753
| ML20217B753 | |
| Person / Time | |
|---|---|
| Issue date: | 04/07/1998 |
| From: | Racquel Powell NRC OFFICE OF ADMINISTRATION (ADM) |
| To: | Jacqueline Thompson AFFILIATION NOT ASSIGNED |
| Shared Package | |
| ML20217B758 | List: |
| References | |
| FOIA-98-86, RULE-PRM-35-7 NUDOCS 9804230123 | |
| Download: ML20217B753 (3) | |
Text
I
)
l
. NRC FORM 464 Part i J.S. NUCLEAR REGULAIORY COMMISSION RESPONSE NUMBER l
s
FL,.,4/PA 98-86
[arg%g 's\\k I
\\
RESPONSE TO FREEDOM OF e
f INFORMATION ACT(FOlA)/ PRIVACY g
k'... '/
ACT (PA) REQUEST TYPE b- -)
M-
RESPONSE
REQuESIER
~
DATE Justine Thornpson
'XPR 0 71998 j
l PART l. -INFORMATION RELEASED (See checked boxes)
]. _.
No additional agency records subject to the request have been located
{
j F_l_ Requested records are available through another public distribution program. See Comments section.
APPENDICES-Agency records subject to the request that are identified in the listed appendices are already available for A
public inspection and copying at the NRC Pubhc Document Room.
APPENDICES Agency records subject to the request that are identified in the listed appendices are being made available for H
public inspection and copying at the NRC Public Document Room.
Q Enclosed is information on how you may obtain access to and the charges for copying records located at the NRC Public Document Room,2120 L Street, NW, Wa'shington, DC.
ry APPE NDICE s '-"
gj Agency records subject to the request are enclosed.
g
[-]- Nec~obs su'bject to the request that contain information originated by or of interest to another Federal agency have bee refered to that agency (see comments section) for a disclosure determination and direct response to you.
Q We are continuing to process your request.
] This completes NRC's action on your request.
PART l.A - FEES b-.
AsouNT *
~
{ l You will be billed by NRC for the amount listed.
[ l None. Minimum fee threshold not met.
I l l You will receive a refund for the amount listed.l } Fees waived.
Esee comments' for detads PART 1.3 -INFORMATION NOT LOCATED OR WITHHELD FROM DISCLOSURE
] No egency records subject to the request have been locat3d.
{1 Certain information in the requested records is being withheld from disclosure pursuant to the exemptions described in and for 2 the reasons stated in Part 11.
]- This determination may be appealed within 30 days by writing to the FOIA/PA Officer, U.S. Nuclear Regulatory Commission.
Washington, DC 20555-0001. Clearly state on the envelope and in the letter that it is a "FOIA/PA Appeal."
PART 1.C COMMENTS (Use attached Comments continuation page if required)
S/
U#
t,ggy Ut]MG300 3M00d i
.r-m, e
F Rt EDOM OF INFyMATION AND PR Cf AC OF F ICE R yl E t I li d l
StGNA AWC Russ). owell
+ * * ' ',.
u, u....=-
~
N REMED PAPER hs fonwn deognehong inFom 900423012'3 480407 PDR FOIA
~~~
THOMPSON 98-86 PDR
,ou, c
4 Froe-CH0PEY TAYLCR & FEIL 4040413221 T-5tB F.0 M 3 F-594
, rge -
p 7.
- e gmy.
Re: FOIA 98-86 APPENDIX A RECORDS ALREADY AVAILABLE IN IHE PDR ACCESSION NQ PATE NUMBER _
DESCRIPTION /PAGE COUNT 1.
11/30/88 8904190105 Letter from H. Cooper, Theragenics Corp, to N McElroy, NRC, regarding Modifications to Titic 10 Part 35A00, with attachments: 1) FDA 510K approval letter,2) Georgia sealed source registration,3) Theraseed product literature,4)
Package insert and Dose Rate Table, and 5) List of Theragenics Management personnel.
8911290100-(
2.
12/20/85 Memorandum from William G. Mcdonald to Eric S. Beckjord, subject: Petition for Rulemaking (PRM 35-7) Filed by Theragonics Corporation; providing copy of petition for review; requesting determination tnat petition quuhfees rur fast-track rulemaking. : Note previously in Central File; can now be released (1 page) 3.
02/22/89 8911290188 Memo from Denton, GPA to Beckjord, RES re-Proposed Amendment to 10 CFR 35.400. Adding Palladium-103 for Interstitial Treatment of Cancer (PRM-35-7) (1 page) 4.
0 28/ 9 8904190078 Propcseo rule 10 CFR 35, "Pa-103 for interststial d'C ~
M T8 Treatment of Cancer' (8 pages).
5.
04/07/89 8908080178 Memo from Beckjord. RES to J B. Breaux, forwaros proposed amend to 10 CFR35 re. reducing burden on medical use licensees planning to use Pd-103 source for interstitial treatment of cancer (4 pages).
8.
04/17/89 8911290061 Proposed ru.e 10 CFR 35, -Pd-103 for Interstitial j
Treatment of Cancer" (2 pages).
7 05/08/89 8905150202 Ltr from O.W. Linton Amencan conege of Radiology, providing comments supperting proposed rule 10 CFR 35 re. use of Pd-103 tor eterstitial treatment of cancer (1 page) 8911290114ek Memo from Denton, GPA rn Rackjord. RES re-8.
8/25/89 providing final concurrence on PRM-35-7. (2 pages) i
1 From-CH0PEY TAYi,CR 4 F11L 4048413111 T-518 F.03/03 F-594 6
k 9.
8/29/89 8911290118 0 Memo Norry, ADM to Beckjord, RES re: Review of the Final Rule on Palladium-103 for interstitial Treatment of Cancer (1 page) j 10.
09/26/89 8910180242
- Pd-103 for interstitial Treatment of Cancer,'
10CFR35 final rule, reoniations amanded to add Pd-103 as sealed source in seeds to list of brachytherapy sources perrrstted for use in treatment of cancer (7 pages).
8911290148ck Memo from Beckjord, RES to Mcdonald, ADM re:
11 11/21/89 Petition for Rulemaking (PRM-35-7) Filed by Theragenics Corporation (1 page) s l
?1 0